【中金：维持信达生物(01801.HK)跑赢行业评级 目标价118.3港元】智通财经APP获悉，中金发布研报称，维持信达生物(01801.HK)跑赢行业评级，基本维持2026年归母净利润预测24.3亿元不变，考虑到国际化拓展所需要费用，下调2027年归母净利润预测5.2%至36.4亿元。考虑到公司积极2030年指引和利润释放确定性提升，基于DCF模型，维持目标价118.3港元不变，较当前股价有18.2%的上行空间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.